Search Medical Condition
Please enter condition
Please choose location from dropdown

Raynaud's Disease Clinical Trials

A listing of Raynaud's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (9) clinical trials

The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )

Systemic sclerosis is a disease with a high burden caused by morbidity and increased mortality. To date a cure for SSc is not available. In this trial, patients are treated very early in the disease which could change the long term outcome of SSc in these patients. In daily practice, ...

Phase N/A

Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma

Systemic sclerosis (SSc) is a multisystem autoimmune illness characterized by vasculopathy, immune system activation and fibrosis of the skin and internal organs. SSc affects approximately 240 people per million in the US, but is a disease for which there is no FDA approved medication. Current hypothesis of pathogenesis suggest that ...


Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

A single center double-blinded, placebo-controlled, crossover study to assess efficacy of oral treprostinil titrated to a tolerable goal dose of 2.0 mg three times per day (TID) in 20 patients with symptomatic primary or secondary Raynaud's Phenomenon resistant to vasodilatory therapy. Based on a pre-screening survey of the clinic population ...

Phase N/A

Diosmiplex (Vasculera ) in Primary and Secondary Raynaud's Phenomenon

Raynaud's phenomenon is a disorder characterized by spasm of digital arteries leading to blanching, coldness and discomfort of the affected digit, affecting up to 3-5% of the population at some time in their lives. Raynaud's is roughly classified into primary and secondary forms. The primary form may occur without apparent ...

Phase N/A

Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.

Raynaud's phenomenon (RP) is a clinical syndrome that results from an excessive vascular reactivity of the microcirculation of the fingers and/or other extremities of the body in response to a stress, mostly cold. Primary RP affects 4 to 6% of the general population and displays important geographic variations. Most secondary ...

Phase N/A

Metabolomic Analysis of Systemic Sclerosis

Currently investigators do not have diagnostic and prognostic markers for SSc which almost always starts with a vascular disease (Raynaud's disease) isolated for several years. The primary purpose is to highlight discriminating metabolic profiles depending on the characteristics of the disease, allowing early diagnosis of SSc at the onset of ...

Phase N/A

Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon

Raynaud's phenomenon: Raynaud's phenomenon is defined by vasospasms occurring in the fingers, toes, nose, ears or tongue lasting for minutes to hours. The attacks of vasospasms are provoked by cold exposure or stressful emotions and present themselves as well demarcated pallor of the skin and may include desensitization of the ...

Phase N/A

Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon

Raynaud's Phenomenon is a disorder that causes pain and functional limitation in people who suffer it. Investigators considerer that the application of an electrotherapy intervention with galvanic current, thanks to its vasodilator action, will produce clinically significant improvements in the number of attacks, temperature and blood flow of patients with ...

Phase N/A

The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon

This prospective double-blind randomized control trial seeks to compare a single formulation of BoNT, aboboutlinum toxin A (Dysport), to a placebo saline group, studying the effect of BoNT on Raynaud's symptoms among a more diverse population to provide insight into the patients most likely to benefit from BoNT.